Suchergebnisse - "O3J8G9O825"

PubPharm (42)

1

Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19

enthalten in: Therapeutic drug monitoring | 2023

von Lemaitre, F. | Budde, K. | Van Gelder, T. | +14

2

Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis

enthalten in: Therapeutic drug monitoring | 2022

von Huang, Y. | Huang, Y. | Wu, T. | +4

3

Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients

enthalten in: Therapeutic drug monitoring | 2021

von Chouchana, L. | Boujaafar, S. | Gana, I. | +13

4

Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil

enthalten in: Therapeutic drug monitoring | 2017

von Lemaitre, F. | Ben Ali, Z. | Tron, C. | +5

5

Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection

enthalten in: Therapeutic drug monitoring | 2016

von Badri, P. | Parikh, A. | Coakley, E. | +4

6

Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction

enthalten in: Therapeutic drug monitoring | 2016

von Cattaneo, D. | Riva, A. | Clementi, E. | +2

7

Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment

enthalten in: Therapeutic drug monitoring | 2014

von Khaykin, P. | Kotzerke, P. | Stephan, C. | +7

8

Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens

enthalten in: Therapeutic drug monitoring | 2013

von Baroncelli, S. | Villani, P. | Galluzzo, C. | +15

9

Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients

enthalten in: Therapeutic drug monitoring | 2013

von Martínez-Rebollar, M. | Muñoz, A. | Pérez, I. | +10

10

Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146

enthalten in: Therapeutic drug monitoring | 2013

von Zhang, X. | Tierney, C. | Albrecht, M. | +6

1
2
3
4
5
Nächster »
[5]